Nonalcoholic Steatohepatitis Clinical Trials

221 clinical trials for Nonalcoholic Steatohepatitis across international registries, including 26 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease — RECRUITING
• Evaluating the Pharmacokinetics and Safety of Miricorilant — RECRUITING · PHASE1
• Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis — RECRUITING
• Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) — RECRUITING · PHASE2
• Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — RECRUITING · PHASE2
• Study of ADI-PEG 20 Versus Placebo in Subjects With NASH — RECRUITING · PHASE2
• To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects — RECRUITING · PHASE1
• Low-Dose Pioglitazone in Patients With NASH (AIM 2) — RECRUITING · PHASE2
• Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis — RECRUITING
• Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance — RECRUITING · NA
• A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III TRIAL EVALUATING LONG-TERM EFFICACY AND SAFETY OF SURVODUTIDE WEEKLY INJECTIONS IN ADULT PARTICIPANTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC ASSOCIATED STEATOHEPATITIS (NASH/MASH) AND (F2) - (F3) STAGE OF LIVER FIBROSIS — RECRUITING · PHASE3
• A PHASE III DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL TO EVALUATE LIVER-RELATED CLINICAL OUTCOMES AND SAFETY OF ONCE WEEKLY INJECTED SURVODUTIDE IN PARTICIPANTS WITH COMPENSATED NON-ALCOHOLIC STEATOHEPATITIS/METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (NASH/MASH) CIRRHOSIS — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH NON-CIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS (SYNCHRONY-HISTOLOGY) — RECRUITING · PHASE3
• A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN ADULTS WITH PRECIRRHOTIC NONALCOHOLIC STEATOHEPATITIS — RECRUITING · PHASE2
• A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFECT OF RESMETIROM ON LIVER-RELATED OUTCOMES IN PATIENTS WITH WELL-COMPENSATED (CHILD-PUGH A) NON-ALCOHOLIC STEATOHEPATITIS (NASH) CIRRHOSIS (MAESTRO-NASH OUTCOMES) — RECRUITING · PHASE3
• 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATMENT OF NASH (HORIZON): A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GSK4532990 IN ADULTS WITH PRE-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS — RECRUITING · PHASE2
• A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF LANIFIBRANOR FOLLOWED BY AN ACTIVE TREATMENT EXTENSION IN ADULT PATIENTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS 2 (F2)/FIBROSIS 3 (F3) STAGE OF LIVER FIBROSIS — RECRUITING · PHASE3
• EFFICACY AND SAFETY INVESTIGATION OF NNC0194-0499 CO-ADMINISTERED WITH SEMAGLUTIDE IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS: A DOSE-RANGING, PLACEBO-CONTROLLED TRIAL — RECRUITING
• THE EFFECT OF SEMAGLUTIDE IN SUBJECTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS — RECRUITING
• A DOUBLE-BLIND RANDOMIZED, PLACEBO-CONTROLLED STUDY AND OPEN-LABEL LONG TERM EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR 80 MG IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WITH INADEQUATE RESPONSE OR INTOLERANCE TO URSODEOXYCHOLIC ACID — RECRUITING
• A SEAMLESS, ADAPTIVE, PHASE 2B/3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, INTERNATIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF BELAPECTIN (GR-MD-O2) FOR THE PREVENTION OF ESOPHOGEAL VARICES IN NASH CIRRHOSIS — RECRUITING · PHASE2
• A PHASE 3, MULTINATIONAL, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF MGL 3196 (RESMETIROM) IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS AND/OR HEPATIC DECOMPENSATION — RECRUITING · PHASE3
• STELLARIS: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS — RECRUITING · PHASE3
• A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF VOLIXIBAT POTASSIUM, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI) IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) — RECRUITING · PHASE2
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS — RECRUITING · PHASE3
• Dietary polyunsaturated fatty acids for decreasing lipid hepatic content in children with fatty liver — ACTIVE_NOT_RECRUITING · PHASE4
• A clinical study to investigate the Effects of Different Doses of the drug product S-adenosyl-L-methionine (SAMe) in patients with Nonalcoholic Steatohepatitis (NASH) and in healthy volunteers as control group — COMPLETED · PHASE3
• Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study — ACTIVE_NOT_RECRUITING · PHASE2
• HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes — COMPLETED · PHASE2
• Evaluation of Miricorilant on Liver Fat in Patients With MASLD — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension — COMPLETED · PHASE2
• Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes — ACTIVE_NOT_RECRUITING
• Vitamin E Dosing Study — COMPLETED · PHASE2
• A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) — COMPLETED
• A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) — ACTIVE_NOT_RECRUITING · PHASE2
• PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE MGL-3196 (RESMETIROM) IN PATIENTS WITH MASH WHO HAVE UNDERGONE LIVER TRANSPLANT FOR MASH CIRRHOSIS OR OTHER ETIOLOGIES — NOT_YET_RECRUITING · PHASE2
• A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR) — SUSPENDED · PHASE3
• A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) — COMPLETED · PHASE2
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) — COMPLETED · PHASE2
• A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis — COMPLETED · PHASE2
• Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis — COMPLETED · PHASE2
• A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis — TERMINATED · PHASE1
• A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor — COMPLETED · PHASE1
• Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis — NOT_YET_RECRUITING · NA
• Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) — COMPLETED · PHASE2
• Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease — COMPLETED · PHASE1
• A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) — TERMINATED · PHASE2
• Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis — COMPLETED · PHASE1

Refine this search